Table 3 Immunotherapy clinical trials within the last 10 years
Target | Treatment | The National Clinical Trial number | Year of completion |
|---|---|---|---|
Immune cells | T cell | NCT03044743 | 2022–03 |
NCT04509726 | 2023–08 | ||
NCT05592626 | 2026–10 | ||
Nature killer cell | NCT03007836 | Completed, 2019–06 | |
Dendritic cell | NCT04476641 | 2022–12 | |
Anti-PD1 | Toripalimab | NCT03925090 | 2023–10 |
NCT04446663 | 2024–12 | ||
NCT04447326 | 2026–06 | ||
NCT04517214 | 2026–12 | ||
NCT05147844 | 2024–03 | ||
NCT05229315 | 2023–12 | ||
NCT05385926 | 2024–04 | ||
NCT05484375 | 2029–09 | ||
NCT05813626 | 2027–10 | ||
NCT04890522 | 2028–12 | ||
NCT03581786 | 2022–10 | ||
NCT04453813 | 2027–07 | ||
NCT04778956 | 2033–03 | ||
NCT05340491 | 2027–12 | ||
NCT05955105 | 2026–07 | ||
NCT03930498 | 2025–12 | ||
Nivolumab | NCT02339558 | Completed, 2018–06 | |
NCT03267498 | 2024–04 | ||
NCT03097939 | 2024–12 | ||
NCT04875611 | 2025–12 | ||
NCT05904080 | 2028–06 | ||
NCT04910347 | 2025–12 | ||
NCT06019130 | 2028–01 | ||
NCT04458909 | Terminated, 2023–08 | ||
NCT06029270 | 2029–04 | ||
Pembrolizumab | NCT03734809 | 2024–12 | |
NCT03813394 | 2024–03 | ||
NCT03082534 | 2024–05 | ||
NCT03809624 | 2025–12 | ||
NCT04825990 | 2028–03 | ||
NCT02611960 | Completed, 2022–09 | ||
NCT03674567 | 2023–12 | ||
NCT02538510 | Completed, 2023–09 | ||
Sintilimab | NCT04872582 | 2024–10 | |
NCT04917770 | 2024–06 | ||
NCT03700476 | 2025–01 | ||
NCT03619824 | 2024–03 | ||
NCT05201859 | 2026–02 | ||
NCT05417139 | 2025–07 | ||
Camrelizumab | NCT04221516 | 2024–02 | |
NCT04782765 | 2025–03 | ||
NCT05011227 | 2025–08 | ||
NCT05097209 | 2026–04 | ||
NCT05128201 | 2026–05 | ||
NCT03427827 | 2026–02 | ||
NCT03707509 | 2022–12 | ||
NCT04453826 | 2028–09 | ||
NCT04944914 | 2026–06 | ||
NCT05524168 | 2025–09 | ||
Penpulimab | NCT03866967 | 2023–12 | |
NCT04220307 | Completed, 2022–08 | ||
NCT04974398 | 2026–09 | ||
Tislelizumab | NCT04833257 | 2026–11 | |
NCT04870905 | 2026–05 | ||
NCT05448885 | 2025–12 | ||
NCT05211232 | 2027–03 | ||
NCT03924986 | 2024–06 | ||
Tirelizumab | NCT05092217 | 2024–10 | |
Peramprizumab | NCT05193617 | 2027–01 | |
Triprilimab | NCT04421469 | 2023–06 | |
PD-1/CTLA-4 | Cadonilimab | NCT05790200 | 2025–09 |
NCT05587374 | 2027–01 | ||
PD-L1 | Envafolimab | NCT05397769 | 2026–12 |
Durvalumab | NCT04447612 | 2024–12 | |
KL-A167 | NCT05294172 | 2025–05 | |
VEGF | Bevacizumab | NCT05341193 | 2025–12 |
NCT05898256NCT03074513 | 2026–07 | ||
NCT05063552 | 2024–06 | ||
2027–12 | |||
EGFR | Nimotuzumab | NCT03708822 | 2026–12 |
NCT04223024 | 2026–12 | ||
NCT04456322 | 2025–06 | ||
TIM-3 | TQB2618 | NCT05563480 | 2024–05 |
HGF | Ficlatuzumab | NCT03422536 | Completed, 2022–04 |
TGF-β receptor | Bintrafusp Alfa | NCT04396886 | 2022–12 |